We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
Read MoreHide Full Article
Shares of biopharmaceutical company Incyte Corporation (INCY - Free Report) have surged 43.8% in the year so far, outperforming 10.3% growth recorded by the industry.
Incyte’s lead drug Jakafi (ruxolitinib) is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera (PV), who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for treating patients with intermediate or high-risk myelofibrosis (MF) including primary MF, post-PV MF, and post-essential thrombocythemia MF.
The FDA recently approved Jakafi for the treatment of steroid-refractory acute GVHD in adult and pediatric patients aged 12 years or above. This is the third indication for which the drug has been approved in the United States. The drug’s performance has been stellar in the year so far. Based on the strong performance of Jakafi in the first nine months of 2019, the company upped its revenue guidance for the same.
Incyte is working to expand the drug’s label into additional indications, which should further boost sales.
Incyte’s efforts to develop its pipeline are highly encouraging. The company has elected to not participate in the development of baricitinib with Eli Lilly (LLY - Free Report) in order to reallocate capital over time to other promising internal projects. The company has some very encouraging candidates, including pemigatinib, itacitinib and capmatinib in its pipeline.
Incyte submitted an NDA to the FDA for pemigatinib seeking approval as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma under Breakthrough Therapy designation. The FDA has accepted the same. With the FDA granting priority review to the NDA, a decision from the regulatory body is expected on May 30, 2020. Incyte is evaluating itacitinib in patients with treatment-naïve GVHD in the GRAVITAS program.
Top-line results from GRAVITAS-301, the phase III study of itacitinib as a treatment for patients with newly diagnosed acute GVHD, are expected shortly. Capmatinib is being developed in collaboration with Novartis (NVS - Free Report) for non-small cell lung cancer (NSCLC) with MET exon-14 skipping mutations. In June 2019, the FDA granted Breakthrough Therapy designation to capmatinib as a treatment for patients with metastatic NSCLC harboring MET exon-14 skipping mutation with disease progression on or after platinum-based chemotherapy.
Hence, we expect the company to maintain momentum in 2020 backed by solid growth in Jakafi and encouraging pipeline progress.
Earnings estimates for 2019 have increased by 40 cents for Alexion in the past 90 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance
Shares of biopharmaceutical company Incyte Corporation (INCY - Free Report) have surged 43.8% in the year so far, outperforming 10.3% growth recorded by the industry.
Incyte’s lead drug Jakafi (ruxolitinib) is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera (PV), who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for treating patients with intermediate or high-risk myelofibrosis (MF) including primary MF, post-PV MF, and post-essential thrombocythemia MF.
The FDA recently approved Jakafi for the treatment of steroid-refractory acute GVHD in adult and pediatric patients aged 12 years or above. This is the third indication for which the drug has been approved in the United States. The drug’s performance has been stellar in the year so far. Based on the strong performance of Jakafi in the first nine months of 2019, the company upped its revenue guidance for the same.
Incyte is working to expand the drug’s label into additional indications, which should further boost sales.
Incyte’s efforts to develop its pipeline are highly encouraging. The company has elected to not participate in the development of baricitinib with Eli Lilly (LLY - Free Report) in order to reallocate capital over time to other promising internal projects. The company has some very encouraging candidates, including pemigatinib, itacitinib and capmatinib in its pipeline.
Incyte submitted an NDA to the FDA for pemigatinib seeking approval as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma under Breakthrough Therapy designation. The FDA has accepted the same. With the FDA granting priority review to the NDA, a decision from the regulatory body is expected on May 30, 2020. Incyte is evaluating itacitinib in patients with treatment-naïve GVHD in the GRAVITAS program.
Top-line results from GRAVITAS-301, the phase III study of itacitinib as a treatment for patients with newly diagnosed acute GVHD, are expected shortly.
Capmatinib is being developed in collaboration with Novartis (NVS - Free Report) for non-small cell lung cancer (NSCLC) with MET exon-14 skipping mutations. In June 2019, the FDA granted Breakthrough Therapy designation to capmatinib as a treatment for patients with metastatic NSCLC harboring MET exon-14 skipping mutation with disease progression on or after platinum-based chemotherapy.
Hence, we expect the company to maintain momentum in 2020 backed by solid growth in Jakafi and encouraging pipeline progress.
Zacks Rank & Another Stock to Consider
Incyte currently carries a Zacks Rank #2 (Buy). Another top-ranked stock in the biotech sector is Alexion Pharmaceuticals , which carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Earnings estimates for 2019 have increased by 40 cents for Alexion in the past 90 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>